Skip to main content
Biotest AG logo

Biotest AG — Investor Relations & Filings

Ticker · BIO3 ISIN · DE0005227201 LEI · 529900JVX7RPXBLYUD89 F Manufacturing
Open in API
Filings indexed 1,148 across all filing types
Latest filing 2020-02-25 Major Shareholding Noti…
Country DE Germany
Listing F BIO3

About Biotest AG

https://www.biotest.com/de/en/index.cfm

Biotest AG is a global company that develops, manufactures, and supplies plasma protein products and biotherapeutic drugs. Sourced from human blood plasma, its products are primarily used in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. The portfolio includes immunoglobulins (e.g., Intratect), coagulation factors, and albumins designed to treat severe and chronic diseases such as immune deficiencies, haemophilia, and coagulation disorders. The company manages the entire value chain from clinical development to sales and is advancing a pipeline of new treatments, including next-generation immunoglobulins (BT595) and fibrinogen concentrates (BT524). Biotest also provides Human Serum Albumin for use as a multifunctional excipient in pharmaceutical and diagnostic applications.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2020
Major Shareholding Notification Classification · 98% confidence The document is explicitly titled 'Notification of Major Holdings' and details changes in voting rights percentages (crossing thresholds) held by a specific entity (J O Hambro Capital Management Limited) in Biotest AG, referencing German Securities Trading Act (WpHG) articles. This type of filing, which reports changes in significant share ownership, directly corresponds to the definition of Major Shareholding Notification (MRQ). Although it mentions 'Voting Rights Announcements' in the header, the content is a specific disclosure of a holding change, not the general results of a vote (DVA).
2020-02-25 English
Biotest AG: Biotest's CMV-specific hyperimmunoglobulin Cytotect CP Biotest receives UK marketing authorisation
Regulatory Filings Classification · 100% confidence The document is a press release dated January 15, 2020, announcing that Biotest AG's product, Cytotect CP Biotest, received UK marketing authorisation following a Repeat Use Procedure (RUP). The content focuses on a specific regulatory/product approval event, not a periodic financial report (like 10-K or IR), a management change (MANG), or a general shareholder vote (AGM-R/DVA). Since this is a specific announcement regarding regulatory success for a product, it fits best under the general 'Regulatory Filings' category (RNS) as it is a news item disseminated via DGAP concerning a regulatory event, which is not covered by more specific codes like ER, AR, or LTR. It is not a report itself, but an announcement of regulatory action.
2020-01-15 English
Biotest AG: Biotest hosts first international symposium to increase awareness for cytomegalovirus infections
Environmental & Social Information Classification · 99% confidence The document is a press release dated December 17, 2019, detailing Biotest AG's hosting of an international symposium on cytomegalovirus (CMV) infections. It discusses scientific insights, market potential for a specific drug (CMV hyperimmunoglobulin), and general company updates related to this medical topic. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a quarterly report (IR). It is an announcement about a corporate event and related business developments, which fits best under the general category of miscellaneous corporate news or a specific announcement that doesn't map directly to the defined financial/governance codes. Since it is a news announcement about a corporate event/topic that isn't strictly about management changes (MANG), director dealings (DIRS), or capital structure (CAP), the most appropriate fallback category is Regulatory Filings (RNS), which serves as the general regulatory announcement/news category.
2019-12-17 English
Biotest AG: Biotest AG opens fourth plasma collection centre in Czech Republic
Regulatory Filings Classification · 100% confidence The document is a short press release dated December 11, 2019, announcing that Biotest AG opened a new plasma collection center in the Czech Republic. It contains company updates, operational news, and contact information, disseminated via DGAP (a service often used for regulatory news dissemination in Germany). It is not a formal financial report (like 10-K or IR), nor is it a transcript, dividend notice, or management change announcement. Since it is a general corporate announcement disseminated through a regulatory news service (DGAP) that doesn't fit the highly specific categories like ER, CAP, or MANG, the most appropriate fallback category is Regulatory Filings (RNS), as it serves as a general corporate news release.
2019-12-11 English
Biotest AG: Biotest AG increases Guidance
Earnings Release Classification · 100% confidence The document is an 'Ad-hoc RELEASE' dated 4 December 2019, announcing that 'Biotest AG increases Guidance' for the 2019 financial year, specifically updating the operating result (EBIT) guidance. This type of announcement, which provides key financial updates outside of a full periodic report (like 10-K or IR), aligns best with an Earnings Release (ER), which covers initial announcements of periodical financial results/highlights. Although it is an ad-hoc disclosure under MAR, the content is a forward-looking guidance update, which is a core component of earnings announcements. It is not a full report (10-K, IR), a transcript (CT), or a management discussion (MDA), but rather the initial release of updated performance expectations. FY 2019
2019-12-04 English
Declaration of Voting Results & Voting Rights Announcements 2019
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is explicitly titled 'Voting Rights Announcements' and contains detailed tables reporting changes in the percentage of voting rights held by a specific entity ('J O Hambro Capital Management Limited') in Biotest AG, referencing German Securities Trading Act (WpHG) sections (Article 40, Sec. 33, 34, 38). This directly corresponds to the definition of a Major Shareholding Notification, which tracks changes in significant ownership thresholds. The code for Major Shareholding Notification is MRQ.
2019-11-18 English

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.